Tags

Type your tag names separated by a space and hit enter

Finasteride treatment for one year in 35 hirsute patients.
Exp Clin Endocrinol Diabetes. 1999; 107(3):195-7.EC

Abstract

This study was performed to confirm the favourable therapeutic effects of finasteride in hirsute women as described by previous publications of different research groups. Our study was a non-randomized, prospective clinical trial. Thirty five patients with hirsutism were included in the study. The patients received 5 mg finasteride orally once per day over a period of 12 months. Hirsutism score, FSH, LH, E2, total T, free T, androstenedione (A), DHEAS, 17-hydroxyprogesterone (17-OHP) and sex hormone-binding globulin (SHBG) levels were determined in all the patients before treatment and every 6 months during treatment. The modified Ferriman-Gallwey score decreased from a mean of 19.06 +/- 6.12 to 11.31 +/- 4.93 during the study. Clinical improvement in the degree of hirsutism was observed in 26 of 35 patients. The percent reductions in hirsutism scores (mean% +/- SD) at 6 and at 12 months were 25.8 +/- 11.3 and 41.3 +/- 18.5, respectively. During the finasteride therapy E2 and SHBG were increased significantly while DHEAS was decreased significantly at 12 months. There were no significant changes in the values of the other hormones and no serious side effects were observed in the study. In conclusion, finasteride is a well tolerated therapeutic agent without significant side pathological laboratory findings and can be used in the treatment of hirsutism.

Links

Publisher Full Text

Authors+Show Affiliations

Bayram F
Department of Endocrinology, Erciyes University, Faculty of Medicine, Kayseri, Turkey.
Müderris II
No affiliation info available
Sahin Y
No affiliation info available
Keleştimur F
No affiliation info available

MeSH

17-alpha-HydroxyprogesteroneAdolescentAdultAndrostenedioneDehydroepiandrosterone SulfateEnzyme InhibitorsEstradiolFemaleFinasterideFollicle Stimulating HormoneHirsutismHumansLuteinizing HormoneProspective StudiesSex Hormone-Binding GlobulinTestosteroneTime Factors

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

10376445

Citation

Bayram, F, et al. "Finasteride Treatment for One Year in 35 Hirsute Patients." Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association, vol. 107, no. 3, 1999, pp. 195-7.
Bayram F, Müderris II, Sahin Y, et al. Finasteride treatment for one year in 35 hirsute patients. Exp Clin Endocrinol Diabetes. 1999;107(3):195-7.
Bayram, F., Müderris, I. I., Sahin, Y., & Keleştimur, F. (1999). Finasteride treatment for one year in 35 hirsute patients. Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association, 107(3), 195-7.
Bayram F, et al. Finasteride Treatment for One Year in 35 Hirsute Patients. Exp Clin Endocrinol Diabetes. 1999;107(3):195-7. PubMed PMID: 10376445.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Finasteride treatment for one year in 35 hirsute patients. AU - Bayram,F, AU - Müderris,I I, AU - Sahin,Y, AU - Keleştimur,F, PY - 1999/6/22/pubmed PY - 1999/6/22/medline PY - 1999/6/22/entrez SP - 195 EP - 7 JF - Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association JO - Exp Clin Endocrinol Diabetes VL - 107 IS - 3 N2 - This study was performed to confirm the favourable therapeutic effects of finasteride in hirsute women as described by previous publications of different research groups. Our study was a non-randomized, prospective clinical trial. Thirty five patients with hirsutism were included in the study. The patients received 5 mg finasteride orally once per day over a period of 12 months. Hirsutism score, FSH, LH, E2, total T, free T, androstenedione (A), DHEAS, 17-hydroxyprogesterone (17-OHP) and sex hormone-binding globulin (SHBG) levels were determined in all the patients before treatment and every 6 months during treatment. The modified Ferriman-Gallwey score decreased from a mean of 19.06 +/- 6.12 to 11.31 +/- 4.93 during the study. Clinical improvement in the degree of hirsutism was observed in 26 of 35 patients. The percent reductions in hirsutism scores (mean% +/- SD) at 6 and at 12 months were 25.8 +/- 11.3 and 41.3 +/- 18.5, respectively. During the finasteride therapy E2 and SHBG were increased significantly while DHEAS was decreased significantly at 12 months. There were no significant changes in the values of the other hormones and no serious side effects were observed in the study. In conclusion, finasteride is a well tolerated therapeutic agent without significant side pathological laboratory findings and can be used in the treatment of hirsutism. SN - 0947-7349 UR - https://www.unboundmedicine.com/medline/citation/10376445/Finasteride_treatment_for_one_year_in_35_hirsute_patients_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0029-1212097 DB - PRIME DP - Unbound Medicine ER -